NEW YORK – A research collaboration between biomedical software startup BostonGene and Weill Cornell Medicine has found that the tumor microenvironment influences the prognosis of patients with diffuse large B-cell lymphoma (DLBCL), suggesting that genomics alone may not provide a complete picture of a patient's disease trajectory.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.